BTIG Maintains Buy on Minimed Group, Raises Price Target to $28

Benzinga Newsdesk www.benzinga.com Positive 84.8%

Neg 0% Neu 0% Pos 84.8%

BTIG analyst Marie Thibault maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $25 to $28.